Title : Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome.

Pub. Date : 2020 Jun 15

PMID : 32305225






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In conclusion, in this network meta-analysis, prasugrel showed the highest efficacy in reducing adverse outcomes in ACS patients and had the highest probability of being the best P2Y12 inhibitor to reduce hard adverse events both at 30-day and 1-year follow-up. Prasugrel Hydrochloride purinergic receptor P2Y12 Homo sapiens